Silverarc Capital Management, LLC Immunovant, Inc. Transaction History

Silverarc Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $626,200 - $883,800	20,000 New	20,000 $842,000
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $1.45 Million - $3.9 Million	219,614 Added 73.2%	519,614 $9.22 Million
Q3 2022 Oct 28, 2022	BUY	$3.93 - $6.37 $1.18 Million - $1.91 Million	300,000 New	300,000 $1.67 Million
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $473,760 - $849,240	-50,400 Closed	0 $0
Q1 2021 May 18, 2021	SELL	$13.08 - $49.6 $648,768 - $2.46 Million	-49,600 Reduced 49.6%	50,400 $808,000
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $3.64 Million - $5.27 Million	100,000 New	100,000 $4.62 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.